NextCell Pharma

The Supplement, which today on 10 June 2024 has been approved by the Swedish Financial Supervisory Authority, forms part of, and must be read together with, the Prospectus. The Prospectus and the Supplement (together the "Prospectuses") are available on the Company's website, www.nextcellpharma.com, and on Redeye's website, www.redeye.se, and will be available on the Swedish Financial Supervisory Authority's website, www.fi.se.

Those who have already subscribed or applied for subscription of units in the Rights Issue are entitled to withdraw their subscription or application within two business days from the publication of the Supplement, i.e. until and including 12 June 2024. Any subscription or application that is not withdrawn within the prescribed time will remain binding and those who wish to remain with their subscription or application do not need to take any further action. Further instructions on how to withdraw a subscription or an application are to be found in the Supplement.

For full terms and conditions and other information on the Rights Issue, please refer to the Prospectuses.

Advisors

Redeye AB is financial advisor to NextCell in connection with the Rights Issue. Törngren Magnell & Partners Advokatfirma KB is legal advisor to the NextCell in connection with the Rights Issue.